Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study

Teresa M. Salgado, Jin Liu, Holly L. Reed, Caroline S. Quinn, Jillian G. Syverson, Jennifer Le-Rademacher, Camden L. Lopez, Andreas S. Beutler, Charles L. Loprinzi, Kiran Vangipuram, Ellen M.Lavoie Smith, N. Lynn Henry, Karen B. Farris, Daniel L. Hertz

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Purpose: Discrepancies between clinicians’ assessment of chemotherapy-induced peripheral neuropathy (CIPN) and patient-reported outcomes (PRO) have been described, though the underlying reasons are unknown. Our objective was to identify potential patient-specific factors associated with under-describing of CIPN to clinicians in women with non-metastatic breast cancer treated with paclitaxel. Methods: Patients enrolled in an observational study (n = 60) completed weekly CIPN PRO using the EORTC CIPN20. Clinician-documented CIPN using the NCI CTCAE were abstracted from the electronic medical record and paired with CIPN20 data at weeks 7 and 10. Patients were classified as under-describers if their CIPN20 was above the 80th percentile of the CIPN20 distribution for that CTCAE grade from an independent clinical trial (N08CA). Demographics, Assessment of Survivor Concerns (ASC), Trust in Oncologist Scale (TiOS), and health literacy assessment were collected post-treatment via survey. Repeated measures cumulative logistic regression models were used to identify factors associated with under-describing CIPN. Results: Forty-two women completed the survey (response rate 70%). Three and 9 patients were categorized as under-describers at weeks 7 and 10, respectively. Women who were not working (OR = 9.00, 95%CI 1.06–76.15), had lower income (OR = 7.04, 95%CI 1.5–32.99), and displayed higher trust in their oncologist's competence (OR = 1.29, 95%CI 1.03–1.62 for a 0.1-unit increase in score) were more likely to under-describe CIPN symptoms. Conclusions: This preliminary study identified non-working status, low income and trust in oncologist's competence as potential factors influencing under-description of CIPN to the clinical team. Further work is needed to clarify these relationships and test additional factors.

Original languageEnglish (US)
Pages (from-to)21-28
Number of pages8
JournalBreast
Volume51
DOIs
StatePublished - Jun 2020

Keywords

  • Breast cancer
  • Chemotherapy-induced peripheral neuropathy
  • Patient reported outcome measures
  • Taxoids

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study'. Together they form a unique fingerprint.

Cite this